Navigation Links
WARF signs license agreement with Pfizer for human embryonic stem cells
Date:5/6/2009

MADISON Pfizer Inc., a major biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, nonprofit patenting and licensing organization for the University of Wisconsin-Madison, announced May 5 that they have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies.

The WARF license provides Pfizer the rights to work with hES cells for drug research and discovery. Securing appropriate licenses, in an area as broad and rapidly moving as regenerative medicine, helps ensure rapid and efficient utilization of the many existing discoveries and inventions in this field and allows for the efficient transfer of information for development of future inventions.

"Our license with WARF provides us with information and materials that will allow us to use their cell lines to explore a whole new range of therapies," says Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine. "Stem cells can be used to create specialized human tissue. Our scientists will determine how new medicines may be able to improve the way stem cells regenerate damaged tissues. We will be optimizing the production of cells that could, one day, be used for therapeutic purposes."

"Pfizer's stem-cell R&D goal is three fold: to use human cells as tools in our drug discovery efforts, to improve the safety of new treatments and, most importantly, to move towards cell therapy," says McKernan. "The benefit to public health could be tremendous as we pursue our discoveries to advance the treatment of debilitating diseases."

"We are pleased to enter into this licensing agreement with Pfizer," said Carl E. Gulbrandsen, managing director of WARF. "Pfizer's access to this key intellectual property may have far-reaching benefits for both public health and Wisconsin's growing biotechnology industry."

As advances in health care help people live longer, the need for new medicines
'/>"/>

Contact: Janet Kelly
jkelly@warf.org
608-890-1491
University of Wisconsin-Madison
Source:Eurekalert

Page: 1 2

Related biology news :

1. Unifying the animate and the inanimate designs of nature
2. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
3. UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity
4. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
5. Engineering technology pinpoints earliest signs of animal life
6. University of Miami engineer designs stretchable electronics with a twist
7. bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC
8. Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimers disease
9. Great Ape Trust signs agreement with Universitas Nasional in Jakarta
10. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
(Date:10/16/2014)... they are anything but sustainable: environmental damage to ... becoming increasingly evident. Despite their disadvantages, however, monocultures ... as the sole possibility of achieving higher yields ... Schmid, an ecology professor at the University of ... and forestry. After all, a new study carried ...
(Date:10/15/2014)... ability to assess the pandemic risk from strains of ... must not allow ourselves to become complacent that the ... consortium of scientists. , Influenza pandemics arise when a ... to develop widespread immunity – spreads in the human ... past 100 years, the worst of which – the ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... The location of an underwater volcanic vent, marked by ... by scientists at the National Oceanography Centre, Southampton. ... the researchers describe how the vent, discovered in a ... we have come to recognise as "classic" hydrothermal vents. ...
... fish are more likely to accept immigrants into their group ... new research shows. The researcher suggests that there are parallels ... research was published today, 6 February 2013, in the journal ... The Princess of Lake Tanganyika ( Neolamprologus pulcher ), a ...
... NEW YORK , Feb. 5, 2013 ... research report is available in its catalogue: ... Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 ... Vascular Endothelial Growth Factor (VEGF), which ...
Cached Biology News:Shimmering water reveals cold volcanic vent in Antarctic waters 2Environmental factors determine whether immigrants are accepted by cooperatively breeding animals 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 3VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 4VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 5
(Date:10/22/2014)... The North American crystal oscillator market report ... analysis and forecast of revenue. This market was valued ... reach $623.6 million by 2018, at a CAGR of ... TOC of the North American crystal oscillator market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... Selexis SA announced today the Company,s president ... Biotech Showcase 2012 Conference held in conjunction with the ... Dr. Fisch will present, "Translating Drug Discovery ... and corporate partners on Monday, January 9 at 11:00 ...
... and AMSTERDAM, Jan. 5, 2012  Agendia, an innovative ... company has signed a contract with Blue Shield ... move paves the way for future in-network coverage ... Cross affiliates across the United States. Developed and ...
... 2012 WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic ... deliver its corporate presentation at the 5 th ... Drake Hotel, San Francisco, Calif., January 9-12, 2012. ... January 10, 2012 beginning at 10:00 a.m. Pacific Time.  ...
Cached Biology Technology:Selexis SA to Present at Biotech Showcase 2012 2Agendia Signs Contract with Blue Shield of California 2WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 2012 2
Narrow-mouth has heavy-duty rim. Approximate graduations are in durable white enamel. Extra large marking space. capacity 125 mL Special grade: student grade...
... Rabbit polyclonal to MSY2/YBOX2 ( ... Antigen: Synthetic ... amino acids 178-227 of human YBX2. ... sequence is proprietary). ...
Standard Fluka For microscopy (Bact., Hist.)...
... are fast multi-channel pipetting platforms consisting of ... with a multi-channel head and a robotic ... with true parallel processing of sample plates ... with the Freedom EVOware program. ...
Biology Products: